Alto Neuroscience, Inc. (ANRO)
(Delayed Data from NYSE)
$10.85 USD
-0.15 (-1.36%)
Updated Oct 21, 2025 04:00 PM ET
After-Market: $10.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Alto Neuroscience, Inc.'s return on equity, or ROE, is -44.34% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that ANRO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ANRO 10.85 -0.15(-1.36%)
Will ANRO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ANRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANRO
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy
ANRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANRO
Analysts’ Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Glaukos (GKOS)
Expansion Breakout appears for ANRO after 80.92% move
Alto Neuroscience price target raised to $16 from $10 at Baird
Alto Neuroscience price target raised by $6 at Baird, here's why
Midday Fly By: AWS hit by outage, Kering sells beauty unit